Art

Reichweite

Bereiche

Status

Start

Ende

Finanzierungsart

Studiendesign

Schlagwörter (Tags)

Projektpartner

Kurzbeschreibung/Zielsetzung

There is a need for more effective therapies for patients with advanced NSCLC driven by the RAS/MEK/ERK pathway. These tumors are generally aggressive, are almost exclusively of non-squamous histology, and represent the largest group of patients with advanced NSCLC harboring specific amutation in Western populations. Based on recent preclinical and clinical evidence, mitogen-activated protein kinase kinase (MEK)-inhibition plus first-line chemotherapy is a promising new treatment for patients with NSCLC and KRAS.